268
Participants
Start Date
October 7, 2024
Primary Completion Date
May 31, 2026
Study Completion Date
December 31, 2028
Lenacapavir Injection
Administered subcutaneously
Lenacapavir Tablet
Administered orally
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Administered orally
CHU Nice Archet, Nice
Hopital Europeen Marseille, Marseille
Hopital Saint Louis - Assistance Publique des Hopitaux de Paris, Paris
APHP Hopital Saint-Antoine, Paris
APHP Bichat Claude-Bernard Hospital, Paris
Hopital Avicenne, Bobigny
University Hospitals Birmingham NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham
Clinical Research Facility, University Hospitals Sussex NHS Foundation Trust, Brighton
Axess Sexual Health, Liverpool University Hospitals NHS Trust, Liverpool
Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, Barts Health NHS Trust, London
Homerton Healthcare NHS Foundation Trust, Homerton University Hospital, London
Caldecot Centre, Kings College Hospital, Kings College Hospital NHS Foundation Trust, London
Chelsea and Westminster Hospital NHS Foundation Trust, Clinical Research Facility, Chelsea and Westminster Hospital, London
Manchester University NS Foundation Trust, Manchester
Lead Sponsor
Gilead Sciences
INDUSTRY